Scarica l'app Stockscreener
3.96
0.75%
-0.03
Dopo l'orario di chiusura:
3.96
Precedente Chiudi:
$3.99
Aprire:
$3.91
Volume 24 ore:
462.51K
Relative Volume:
0.66
Capitalizzazione di mercato:
$236.01M
Reddito:
$40.37M
Utile/perdita netta:
$-119.72M
Rapporto P/E:
-1.941
EPS:
-2.0402
Flusso di cassa netto:
$-135.06M
1 W Prestazione:
-4.12%
1M Prestazione:
-4.58%
6M Prestazione:
-16.10%
1 anno Prestazione:
+16.13%
Intervallo 1D:
$3.80
$3.96
Intervallo di 1 settimana:
$3.77
$4.15
Portata 52W:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.96 | 236.01M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
If You Invested $1,000 in Voyager Therapeutics Inc (VYGR) - Stock Titan
VYGR SEC FilingsVoyager Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Voyager Therapeutics CEO Sandrock sells $44,547 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock - MarketBeat
Voyager Therapeutics (VYGR) CEO sells shares for RSU tax withholding - Stock Titan
Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below 50-Day Moving AverageShould You Sell? - MarketBeat
Issuer (NASDAQ: VYGR) Form 144 — 11,511 common shares listed - Stock Titan
Will Voyager Therapeutics Inc stock hit new highs in YEARWeekly Profit Summary & Stock Portfolio Risk Control - baoquankhu1.vn
Voyager Therapeutics (VYGR) price target increased by 12.22% to 17.17 - MSN
Market Overview: Is GCMGW showing insider buying2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Gap Down: How does Voyager Therapeutics Inc compare to its peersMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Returns Recap: Is Voyager Therapeutics Inc subject to activist investor interest2026 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Activity Recap: Is Voyager Therapeutics Inc subject to activist investor interest2026 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Vanguard disaggregates holdings after realignment (VYGR) — reports 0% ownership - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by Truist Financial - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Strong-Buy at Truist Financial - marketbeat.com
Short Covering: Can Voyager Therapeutics Inc reach all time highs this year2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Voyager Therapeutics Inc stock a smart retirement pickMarket Trend Review & Breakout Confirmation Alerts - baoquankhu1.vn
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut - Yahoo Finance
Published on: 2026-03-22 03:58:04 - baoquankhu1.vn
HC Wainwright Analysts Increase Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics at Stifel 2026 CNS Forum: Year of Tau Focus - Investing.com Canada
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Analysts Set Expectations for VYGR Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Voyager Therapeutics (VYGR): Analyst Reiterates Buy Rating and M - GuruFocus
Voyager Therapeutics' (VYGR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Truist reiterates Buy on Voyager Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Voyager Therapeutics stock ahead of data - Investing.com
Voyager Therapeutics Stock (ISIN: US92916U1025) Eyes Major Upside Amid Gene Therapy Pipeline Momentu - AD HOC NEWS
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen - MarketBeat
Insider Trends: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results? - simplywall.st
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) - The Globe and Mail
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - The Globe and Mail
Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright - The Globe and Mail
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and Statistics - IndexBox
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):